Federal Register of Legislation - Australian Government

Primary content

PB 55 of 2019 Determinations/Health as made
This instrument amends Schedules 3 and 4 of the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008) to reflect amendments made to the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012), commencing on the same day.
Administered by: Health
Registered 28 Jun 2019
Tabling HistoryDate
Tabled HR02-Jul-2019
Tabled Senate02-Jul-2019
Date of repeal 17 Sep 2019
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 55 of 2019

 

National Health Determination under paragraph 98C(1)(b) Amendment 2019 (No. 5)

 

National Health Act 1953

___________________________________________________________________________

 

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under paragraph 98C(1)(b) of the National Health Act 1953.

 

Dated   27 June 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health


___________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health Determination under paragraph 98C(1)(b) Amendment 2019 (No. 5).

(2)          This Instrument may also be cited as PB 55 of 2019.

2          Commencement

This Instrument commences on 1 July 2019.

3          Amendments to Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008)

Schedule 1 amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008).

 


Schedule 1 Amendments

[1]        Schedule 3, after entry for Methylphenidate in the form Tablet containing methylphenidate hydrochloride 54 mg (extended release)

insert:

 

Capsule containing methylphenidate hydrochloride 10 mg (modified release)

[2]        Schedule 4, omit entry for Amino acid formula with fat, carbohydrate, without phenylalanine¬†

[3]        Schedule 4, entry for Amoxicillin with clavulanic acid

substitute:

Amoxicillin with clavulanic acid

Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL

 

Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL